KRYS

KRYS

Last Updated:

Q3'20

Krystal Biotech

Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases. Our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. We work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (Aristotle)

Cash

$286.4M

Burn Rate (Qtr)

-$9.6M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

B-VEC (Topical Beremagene Geperpavec)

Dystrophic Epidermolysis Bullosa (DEB)

Phase 3 (Top-line Data & BLA)

2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon